Module 16: Protein, Antibody & Protein-Protein Modeling
Extend structure-based design from small-molecule pockets to flexible protein interfaces, antibody paratopes, multispecific architectures, and developability-aware protein engineering.
Learning outcomes
- Explain how protein and antibody modeling differs from small-molecule docking.
- Build an ensemble-aware antibody or engineered-protein model.
- Use experimental restraints to constrain and validate protein-protein docking.
- Evaluate interface quality alongside stability, aggregation, and other developability risks.
Interactive interface-ranking exercise
Which protein-complex pose would you advance?
Raw energy favors Pose A. Add independent evidence to test whether that ranking survives clashes, experimental restraints, conformational uncertainty, and developability risk.
Current decision
Advance Pose A
96/100
This decision uses only the docking-energy rank and is a hypothesis, not a validated interface.
#1 Pose A
consensus 96- Energy
- 96
- Restraints
- 42%
- Clashes
- 8
- Ensemble
- 1/5
- Developability
- 35
#2 Pose B
consensus 82- Energy
- 82
- Restraints
- 91%
- Clashes
- 1
- Ensemble
- 4/5
- Developability
- 72
#3 Pose C
consensus 70- Energy
- 70
- Restraints
- 76%
- Clashes
- 0
- Ensemble
- 3/5
- Developability
- 90
Teaching model: these normalized values illustrate evidence integration; they are not physical energies or a universal scoring function. In a real project, predefine acceptance criteria and challenge the leading poses experimentally.
1. Why protein therapeutics need a different modeling stack
Antibodies, nanobodies, engineered binders, enzymes, and multispecific proteins operate through large, flexible interfaces. Their models must represent sequence, fold, loop uncertainty, oligomerization, glycosylation, electrostatics, conformational change, and manufacturability.
Small molecule
A compact ligand is usually docked into a comparatively localized pocket. Search emphasizes ligand conformation, pose, and receptor flexibility.
Protein-protein complex
Two large surfaces must be oriented while side chains, loops, and sometimes domains reorganize. Shape complementarity alone produces many false poses.
Antibody-antigen complex
Six CDR loops create the paratope, but framework residues, orientation of variable domains, glycans, and long CDR-H3 conformations can influence recognition.
Multispecific format
Multiple binding arms introduce valency, linker geometry, avidity, competing target sinks, assembly risk, and tissue-distribution constraints.
2. Antibody structure and sequence annotation
| Element | Modeling question | Common failure mode |
|---|---|---|
| Framework | Is the template close in sequence and canonical geometry? | A poor framework shifts the relative orientation of binding loops. |
| CDR loops | Which numbering scheme and boundary definition are being used? | Residue positions are compared across incompatible schemes. |
| CDR-H3 | How uncertain are length, kink, base, and loop conformations? | One highly uncertain model is treated as a solved paratope. |
| VH/VL orientation | Does the template support the intended interface geometry? | Correct local loops are combined with the wrong domain orientation. |
| Fc and glycans | Are effector function, FcRn interaction, and glycosylation relevant? | A truncated model is used for whole-antibody conclusions. |
3. Building an antibody or engineered-protein model
- 1
Curate the sequence
Confirm chain boundaries, signal peptides, mutations, disulfides, numbering, construct tags, linkers, and intended oligomeric state.
- 2
Select templates or predictions
Choose frameworks and domain orientations using sequence and structural compatibility. Use prediction confidence to define, not hide, uncertain regions.
- 3
Model loops and side chains as an ensemble
Generate alternatives for CDR-H3, engineered loops, and interface side chains. Filter clashes and poor stereochemistry before complex modeling.
- 4
Add relevant chemistry
Represent disulfides, glycans, protonation, post-translational modifications, metals, and linker geometry when they affect the question.
- 5
Validate against data
Use known mutagenesis, epitope mapping, competition, crosslinking, HDX, cryo-EM density, or homologous complexes to challenge the model.
4. Protein-protein and antibody-antigen docking
Protein docking explores rigid-body orientation first, then refines interfaces. Unconstrained global docking is difficult because the surface is large and flexibility is expensive; experimental restraints sharply reduce the search space.
| Evidence | How it constrains docking | Caution |
|---|---|---|
| Known epitope/paratope residues | Defines attractive or ambiguous interaction restraints | A functional residue may act indirectly rather than contact the partner. |
| Crosslinks | Restricts pairs to a distance range | Account for linker length, side-chain geometry, and uncertainty. |
| Mutagenesis | Prioritizes interface patches and tests refined poses | Loss of binding can result from destabilization. |
| Competition or homologous complex | Restricts the face and orientation of binding | Homologous partners may use different loops or angles. |
| Density or low-resolution shape | Filters rigid-body poses globally | Flexible regions may not be resolved. |
5. Interface scoring and validation
Geometry
Check buried surface area, shape complementarity, clashes, cavities, unsatisfied polar groups, and interface planarity. Remove impossible poses before interpreting energy.
Chemistry
Inspect salt bridges, hydrogen-bond networks, aromatic and cation-pi contacts, hydrophobic patches, water mediation, and electrostatic complementarity.
Robustness
Compare scoring functions, refinement protocols, starting structures, and ensemble members. Stable conclusions survive reasonable modeling choices.
Experimental falsification
Select mutations or binding measurements that distinguish competing poses. The most useful model proposes a test that could prove it wrong.
6. Protein engineering and developability
| Risk | Sequence/structure signals | Engineering response |
|---|---|---|
| Low stability | Buried unsatisfied groups, cavities, poor packing, exposed hydrophobics | Stabilize the core or interface while preserving function. |
| Aggregation | Large hydrophobic or charged surface patches and flexible exposed segments | Reduce patchiness, improve colloidal behavior, and test concentration dependence. |
| Polyspecificity | Broad hydrophobic or electrostatic complementarity | Balance paratope chemistry and screen nonspecific binding experimentally. |
| Chemical liabilities | Deamidation, isomerization, oxidation, cleavage, or unpaired cysteine motifs | Remove hotspots when compatible with activity and structure. |
| Immunogenicity | Potential T-cell epitopes, non-human framework content, aggregates | Humanize and de-risk with sequence, structure, and experimental evidence. |
| Poor multispecific geometry | Steric occlusion, strained linkers, incompatible arm spacing | Model full-format architecture and test simultaneous engagement. |